Identification of Specific Biomarkers and Pathways in the Treatment Response of Infliximab for Inflammatory Bowel Disease: In-Silico Analysis.

Rachid Kaddoura Hardik Ghelani Fatma Al QutamiHala AltaherMahmood Yaseen Hachim Reem Kais Jan

Published in: Life (Basel, Switzerland) (2023)

We hypothesize that alteration in the expression of these genes leads to an impaired response to infliximab in IBD patients. Thus, these genes can serve as potential biomarkers for the early detection of compromised infliximab response in IBD patients.

Keyphrases

end stage renal disease
newly diagnosed
ulcerative colitis
ejection fraction
chronic kidney disease
genome wide
bioinformatics analysis
transcription factor
molecular docking
patient reported outcomes
molecular dynamics simulations